PADI4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL243968	0.68	16/20
SCHEMBL243969	0.68	16/20
SCHEMBL245342	0.68	13/20
SCHEMBL245343	0.68	13/20
SCHEMBL935324	0.62	9/20
SCHEMBL935325	0.62	9/20
SCHEMBL1388417	0.43	8/20
SCHEMBL158990	0.60	6/20
SCHEMBL971992	0.53	6/20
SCHEMBL188589	0.51	5/20
SCHEMBL188590	0.51	5/20
SCHEMBL960211	0.38	5/20
SCHEMBL960212	0.38	5/20
Simpinicline (SCHEMBL1333721)	0.33	5/20
Simpinicline (SCHEMBL1333724)	0.33	5/20
SCHEMBL1367541	1.00	4/20
SCHEMBL1367544	1.00	4/20
SCHEMBL1369067	1.00	4/20
SCHEMBL1365749	0.76	4/20
SCHEMBL1365750	0.76	4/20

Clinical trials — most relevant to PADI4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Vascular Function Intervention Trial in Sickle Cell Disease	PHASE2/PHASE3	UNKNOWN
Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial	PHASE3	COMPLETED
Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency	PHASE3	COMPLETED
L-Arginine in Pre-Eclampsia	PHASE3	COMPLETED
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis	PHASE2	RECRUITING
Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19	PHASE2	COMPLETED
ADI-PEG20, Obesity and Prediabetes	PHASE2	WITHDRAWN
Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients	PHASE2	COMPLETED
Impact of Colchicine and Low-dose Naltrexone on COVID-19	PHASE2	COMPLETED
iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.	EARLY_PHASE1	COMPLETED
Arginase Inhibition in Humans With Obesity	EARLY_PHASE1	COMPLETED
Serum Anti-PCOLCE as Novel Diagnostic Biomarker in Rheumatoid Arthritis With Emphasis on Seronegative Patients.	nan	NOT_YET_RECRUITING
Effect of Nonsurgical Periodontal Therapy (NSPT) on Rheumatoid Arthritis Subjects With Periodontitis	nan	COMPLETED
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)	nan	RECRUITING
Study of the Articular Microbiota in Rheumatoid Arthritis.	nan	COMPLETED
Clinical Trial for Evaluation of Vermillion's Blood Test to Predict the Probability of Peripheral Artery Disease	nan	COMPLETED
Effect Assessment of Periodontal Prophylaxis on Rheumatoid Arthritis Activity.	nan	COMPLETED
Effects of Trehalose and Polyphenols in Vasculopathic Patients	nan	COMPLETED
Study of Arginine and Nitric Oxide in Patients With Diabetes	nan	COMPLETED
Effect of Arginine and Glutamine on Radiation-induced Oral Mucositis: a Trible Blinded Randomized Controlled Clinical Trial	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD	nan	COMPLETED
Arginine Synthesis in Healthy Adult Humans	nan	COMPLETED
Study on PAD and CAS Based on Omics and Imaging	nan	NOT_YET_RECRUITING
Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Diabetes	nan	UNKNOWN
A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA	nan	COMPLETED
L-Arginine, Symmetrical and Asymmetrical Dimethylarginine (SDMA/ADMA) in Acute Kidney Injury (AKI)	nan	COMPLETED
Effects of Citrulline on Gut Functioning During Excercise	nan	UNKNOWN
The Clinical Value of the Nitric Oxide System Components in Asthma and COPD	nan	UNKNOWN
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PADI4 binder may also engage these)

Protein	Name	Similarity
O88807	—	1.000	O88807 →
PADI2	Protein-arginine deiminase type-2	1.000	landscape →
PADI1	Protein-arginine deiminase type-1	1.000	landscape →
P20717	—	1.000	P20717 →
Q08642	—	0.997	Q08642 →
Q9Z184	—	0.997	Q9Z184 →
Q8K3V4	—	0.997	Q8K3V4 →
Q9Z183	—	0.996	Q9Z183 →
O88806	—	0.995	O88806 →
O02849	—	0.995	O02849 →
PADI3	Protein-arginine deiminase type-3	0.995	landscape →
Q9Z185	—	0.994	Q9Z185 →
PADI6	Inactive protein-arginine deiminase type-6	0.993	landscape →
P70708	—	0.993	P70708 →
Q95JI2	—	0.984	Q95JI2 →
P06623	—	0.984	P06623 →
Q8TDB6	—	0.983	Q8TDB6 →
AS3MT	Arsenite methyltransferase	0.983	landscape →
Q5R5W9	—	0.983	Q5R5W9 →
P0DP43	—	0.982	P0DP43 →
KDM5B	Lysine-specific demethylase 5B	0.982	landscape →
Q9D2K4	—	0.982	Q9D2K4 →
A6NC97	—	0.982	A6NC97 →
B8JKF4	—	0.982	B8JKF4 →
Q8BMD7	—	0.982	Q8BMD7 →
Q0VA04	—	0.982	Q0VA04 →
KDM5D	Lysine-specific demethylase 5D	0.982	landscape →
TRPV1	Transient receptor potential cation channel subfamily V member 1	0.982	landscape →
Q9D5Z5	—	0.982	Q9D5Z5 →
A1A4J7	—	0.981	A1A4J7 →